Cobra Biologics and Symbiosis Awarded £1.9m ($2.5m USD) Innovate UK Grant

Cobra Biologics, an international contract development and manufacturing organisation (CDMO) of biologics and pharmaceuticals, and Symbiosis Pharmaceutical Services, a contract manufacturing organisation (CMO) specialising in sterile Fill Finish, today announced that they have been awarded a 16-month collaborative grant of £1.9m from Innovate UK. The grant will position the partner companies as globally recognised centres of excellence in the field and firmly establish commercial viral vector manufacturing capabilities within the UK. The joint investment project, costing £4.8m in total, aims to develop world leading capabilities for clinical and commercial production of gene and immunotherapy viral vectors for both drug substance and drug product manufacturing.